{"nctId":"NCT02739984","briefTitle":"Evaluation of Evolocumab (AMG 145) Efficacy in Diabetic Adults With Hypercholesterolemia/Mixed Dyslipidemia","startDateStruct":{"date":"2016-05-17","type":"ACTUAL"},"conditions":["Hypercholesterolemia","Mixed Dyslipidemia","Type 2 Diabetes"],"count":424,"armGroups":[{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo to Evolocumab"]},{"label":"Evolocumab","type":"EXPERIMENTAL","interventionNames":["Biological: Evolocumab"]}],"interventions":[{"name":"Evolocumab","otherNames":["Repatha","AMG 145"]},{"name":"Placebo to Evolocumab","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Male or female ≥ 18 years\n* Type 2 Diabetes Mellitus\n* Hemoglobin A1c \\< 10%\n* Stable diabetes therapy\n* Must be on maximally tolerated dose of statin of at least moderate Intensity\n* Fasting triglycerides ≤ 600 mg/dL\n* Not at LDL-C or Non-HDL-C goal.\n\nExclusion Criteria:\n\n* Moderate to severe renal dysfunction\n* Uncontrolled hypertension\n* Persistent active liver disease or hepatic dysfunction\n* Has taken a cholesterylester transfer protein inhibitor in the last 12 months,\n* Myocardial infarction, unstable angina, percutaneous coronary intervention, coronary artery bypass graft or stroke within 3 months prior to randomization","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percent Change From Baseline in LDL-C at the Mean of Weeks 10 and 12","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.84","spread":"1.76"},{"groupId":"OG001","value":"-64.98","spread":"1.31"}]}]}]},{"type":"PRIMARY","title":"Percent Change From Baseline in LDL-C at Week 12","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.14","spread":"1.92"},{"groupId":"OG001","value":"-54.28","spread":"1.42"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in LDL-C at the Mean of Weeks 10 and 12","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-8.3","spread":"2.2"},{"groupId":"OG001","value":"-75.5","spread":"1.6"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in LDL-C at Week 12","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-8.6","spread":"2.3"},{"groupId":"OG001","value":"-64.4","spread":"1.7"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Non-HDL-C at the Mean of Weeks 10 and 12","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.05","spread":"1.63"},{"groupId":"OG001","value":"-56.62","spread":"1.21"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Non-HDL-C at Week 12","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.60","spread":"1.79"},{"groupId":"OG001","value":"-46.89","spread":"1.33"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Apolipoprotein B at the Mean of Weeks 10 and 12","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.31","spread":"1.58"},{"groupId":"OG001","value":"-50.17","spread":"1.18"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Apolipoprotein B at Week 12","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.78","spread":"1.73"},{"groupId":"OG001","value":"-40.34","spread":"1.29"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Total Cholesterol at the Mean of Weeks 10 and 12","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.13","spread":"1.24"},{"groupId":"OG001","value":"-42.19","spread":"0.92"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Total Cholesterol at Week 12","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.23","spread":"1.36"},{"groupId":"OG001","value":"-34.97","spread":"1.01"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Mean LDL-C at Weeks 10 and 12 Less Than 70 mg/dL (1.8 mmol/L)","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14.8","spread":null},{"groupId":"OG001","value":"92.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With LDL-C at Week 12 Less Than 70 mg/dL (1.8 mmol/L)","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15.4","spread":null},{"groupId":"OG001","value":"84.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With at Least a 50% Reduction From Baseline in Mean LDL-C at Weeks 10 and 12","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.7","spread":null},{"groupId":"OG001","value":"84.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With at Least a 50% Reduction From Baseline in LDL-C at Week 12","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.8","spread":null},{"groupId":"OG001","value":"65.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Lipoprotein(a) at the Mean of Weeks 10 and 12","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.63","spread":"3.29"},{"groupId":"OG001","value":"-30.87","spread":"2.43"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Lipoprotein(a) at Week 12","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.38","spread":"3.06"},{"groupId":"OG001","value":"-25.18","spread":"2.28"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Triglycerides at the Mean of Weeks 10 and 12","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.61","spread":"2.94"},{"groupId":"OG001","value":"-12.64","spread":"2.19"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Triglycerides at Week 12","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.81","spread":"3.41"},{"groupId":"OG001","value":"-8.90","spread":"2.52"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in HDL-C at the Mean of Weeks 10 and 12","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.57","spread":"1.25"},{"groupId":"OG001","value":"7.23","spread":"0.93"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in HDL-C at Week 12","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.41","spread":"1.38"},{"groupId":"OG001","value":"5.96","spread":"1.02"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in VLDL-C at the Mean of Weeks 10 and 12","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.42","spread":"2.57"},{"groupId":"OG001","value":"-13.64","spread":"1.89"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in VLDL-C at Week 12","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.02","spread":"2.94"},{"groupId":"OG001","value":"-10.31","spread":"2.15"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":2,"n":141},"commonTop":["Diabetes mellitus","Hypertension","Diarrhoea","Viral upper respiratory tract infection","Headache"]}}}